Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
about
Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversityEnterovirus and parechovirus infection in children: a brief overviewDevelopment of Novel Vaccines against Enterovirus-71Recent Progress towards Novel EV71 Anti-Therapeutics and VaccinesIs a multivalent hand, foot, and mouth disease vaccine feasible?Cyclical Patterns of Hand, Foot and Mouth Disease Caused by Enterovirus A71 in MalaysiaInactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic MouseThe Current Status of the Disease Caused by Enterovirus 71 Infections: Epidemiology, Pathogenesis, Molecular Epidemiology, and Vaccine DevelopmentEnterovirus 71 infection and neurological complicationsEV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseasesThe Suramin Derivative NF449 Interacts with the 5-fold Vertex of the Enterovirus A71 Capsid to Prevent Virus Attachment to PSGL-1 and Heparan SulfateEfficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in MiceEnterovirus 71 infection and vaccines.Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy.EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD).The effect of meteorological variables on the transmission of hand, foot and mouth disease in four major cities of shanxi province, China: a time series data analysis (2009-2013).EV71 vaccines: a milestone in the history of global vaccine developmentAnimal models of enterovirus 71 infection: applications and limitations.Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 miceRecombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in miceAn inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay.Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development.How to understand the efficacy measurements for enterovirus type 71 vaccine?Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques.Circulation of Coxsackievirus A6 in hand-foot-mouth disease in Guangzhou, 2010-2012.Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDCCoxsackievirus A16: epidemiology, diagnosis, and vaccine.EV71 vaccine, an invaluable gift for children.The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period.Epidemiological analysis, detection, and comparison of space-time patterns of Beijing hand-foot-mouth disease (2008-2012).Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central ChinaEpidemiological and etiological characteristics of hand, foot, and mouth disease in Henan, China, 2008-2013Echovirus 7 associated with hand, foot, and mouth disease in mainland China has undergone a recombination event.The Epidemiological Study of Coxsackievirus A6 revealing Hand, Foot and Mouth Disease Epidemic patterns in Guangdong, ChinaSpatiotemporal Dynamics of Hand-Foot-Mouth Disease and Its Relationship with Meteorological Factors in Jiangsu Province, China.Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn miceImmunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations.
P2860
Q21132297-271F1199-4AC4-4664-B5C1-55AFC93C4B54Q26751373-353D630E-CF34-4DE4-9520-40818DCCD192Q26771247-E9A0F2A9-9A09-49F0-A849-BE68D87749C4Q26775734-6389D59D-FC6E-42F3-AB89-7DD59D0AE76FQ27010349-B759C895-AA5F-40A4-9A0F-C74FB427D150Q27303732-74CFE13F-9BD0-4119-9301-3E9BA3B3D15AQ27321616-B3090F04-D6D4-4CB9-98A7-5531093BC2E0Q28066400-0C4FC6D0-25ED-4919-A0B1-217CEB503E60Q28072189-DCB89D85-CCB6-48BF-BE82-83946EC6E633Q28076658-10BB832B-A133-4890-8D7C-D9A3065A4662Q28550039-791FC887-EBEC-48C3-89AE-2209BF236933Q28606867-EA8E5FDF-B85B-44FD-AA55-20AD9DBE3F5DQ30238518-F0427CA3-6E5B-45A9-97EB-833CCF360E1AQ30249022-FC7102C4-DBF4-4A4C-8BAD-6D5A198B81D9Q30383172-4299D83D-152D-4678-A11A-4E687DA29668Q30904705-4BBE1B01-2D69-47A1-8528-1DE450085D14Q33561240-5D73416B-FB34-46D9-8526-C70168E29181Q33579809-6AB6ABEC-8F5B-43D2-B146-1EABBFD26CBFQ33602804-230AF475-0301-4E37-8654-5DAB39CE64ACQ33646488-BDA6C41D-575C-4425-A2EB-49D13B0F2F59Q33724967-EE1D520E-F31E-4777-B3F1-ED247951582EQ33806668-AB3390F5-F9C6-4173-8CCA-978EE84F0799Q33809953-6145E761-9242-47E9-BAD5-1301F8D403E6Q33887710-814AF455-42C9-43F1-B2DB-DEEE0661DAC7Q34033907-8F2707F5-CF42-403E-84D3-280F946F1DBDQ34149853-460530EF-3F2F-4B21-B805-540034B06A83Q34217390-A38EC66B-C7BF-4819-840A-15B68AEBCC27Q34289974-7CC1B55F-2024-4736-A48A-D62B163E33F6Q34290731-718891DA-875A-4CFE-A513-5C0E38694B70Q34540559-B27269DC-F7A5-45BC-9C0B-47197CE1D016Q34596364-BBEC3E38-B965-443C-AD4E-421BD140F143Q35063743-B2621C03-36B0-4A2E-AE53-A46FDC55750FQ35129310-05A0FBA2-DAC5-4B34-A7BF-613D89DA1843Q35158936-0E939D53-DE5B-4D7C-843F-00356C111793Q35160633-6BF0A28A-A581-4199-B3C1-E513FD6CF93CQ35547015-D3AE9E25-0C60-4F24-B0E1-5E390DDB039FQ35632537-E85A4FC5-4434-4A2A-9278-5B619ADE532FQ35677357-6A2220D9-1E71-4EF9-9E1A-A5B59B3AE407Q35689929-98685B2C-DE37-4207-9FF4-5F57DB3E8C15Q35779269-669105BB-A58B-4448-A8D9-42F800740BA5
P2860
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@ast
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@en
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@nl
type
label
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@ast
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@en
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@nl
prefLabel
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@ast
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@en
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@nl
P2093
P921
P1433
P1476
Efficacy, safety, and immunolo ...... ebo-controlled, phase 3 trial.
@en
P2093
Fan-Yue Meng
Feng-Cai Zhu
Feng-Ji Luo
Heng-Ming Ge
Jing-Xin Li
Li-Wen Zhu
P304
P356
10.1016/S0140-6736(13)61049-1
P407
P577
2013-05-29T00:00:00Z